Lipoic acid in multiple sclerosis: A pilot study

Multiple Sclerosis

Volumn 11, Issue 2, 2005, Pages 159-165

  Yadav, V ^a,b   Marracci, G ^a,b   Lovera, J ^a,b   Woodward, W ^b   Bogardus, K ^b   Marquardt, W ^b   Shinto, L ^b   Morris, C ^c   Bourdette, Dennis N ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antioxidant; Intercellular adhesion molecule 1; Lipoic acid; Matrix metalloproteinase 9; Multiple sclerosis; Pharmacokinetics

Indexed keywords

GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MICROCRYSTALLINE CELLULOSE; PLACEBO; QUERCETIN; THIOCTIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BLOOD SAMPLING; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG INHIBITION; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER TOXICITY; MALE; MULTIPLE SCLEROSIS; NAUSEA; PILOT STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTIOXIDANTS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; SOLUBILITY; THIOCTIC ACID;

EID: 15544390831     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1143oa     Document Type: Article

References (47)

1. Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 1999; 46: 253-56.
2. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999; 12: 309-21.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl J Med 2000; 343: 938-52.
4. Dietrich J, Menne C, Lauritsen JP, von Essen M, Rasmussen AB, Odum N et al. Ligand-induced TCR down-regulation is not dependent on constitutive TCR cycling. J Immunol 2002; 168: 5434-40.
5. Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, Livrea P et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-28.
6. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001; 36: 249-57.
7. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000; 107: 140-47.
8. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999; 94: 1-14.
9. Madri JA, Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immunol 2000; 7: 103-16.
10. Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000; 43: 1085-93.
11. Bloom BJ, Nelson SM, Alario AJ, Miller LC, Schaller JG. Synovial fluid levels of E-selectin and intercellular adhesion molecule-1: relationship to joint inflammation in children with chronic arthritis. Rheumatol Int 2002; 22: 175-77.
12. Nielsen OH, Langholz E, Hendel J, Brynskov J. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci 1994; 39: 1918-23.
13. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29 875-82.
14. Simundic AM, Basic V, Topic E, Demarin V, Vrkic N, Kunovic B et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med 2004; 27: 86-92.
15. Kamijikkoku S, Murohara T, Tayama S, Matsuyama K, Honda T, Ando M et al. Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: a marker of vascular inflammation and a risk of early restenosis? Am Heart J 1998; 136: 231-36.
16. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-25.
17. Rieckmann P, Altenhofen B, Riegel A, Kallmann B, Felgenhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Mult Scler 1998; 4: 178-82.
18. Khoury SJ, Orav EJ, Guttmann CR, Kikinis R, Jolesz FA, Weiner HL. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology 1999; 53: 758-64.
19. Giovannoni G, Miller DH, Losseff NA, Sailer M, Lewellyn-Smith N, Thompson AJ et al. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 2001; 248: 487-95.
20. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121: 2327-34.
21. Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 131: 104-14.
22. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146-53.
23. Marracci G, McKeon GP, Marquardt VVE, Winter RW, Riscoe MK, Bourdette DN. Alpha lipoic acid inhibits human T-cell migration: Implications for multiple sclerosis. J Neurosci Res 2004; 78: 362-70.
24. Ziegler D, Gries F. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997; 46: S62-66.
25. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107: 421-30.
26. Ziegler D, Hanefeld M, Ruhnau K, Hasche H, Lobisch M, Schutte K et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999; 22: 1296-301.
27. McDonald W, Compston A, Edan G, Goodkin DE, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
28. Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
29. Sen CK, Roy S, Khanna S, Packer L. Determination of oxidized and reduced lipoic acid using high-performance liquid chromatography and coulometric detection. Methods Enzymol 1999; 299: 239-46.
30. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.
31. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397-401.
32. Stüve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997; 80: 38-46.
33. Lee HA, Hughes DA. Alpha-lipoic acid modulates NF-kappaB activity in human monocytic cells by direct interaction with DNA. Exp Gerontol 2002; 37: 401-10.
34. Suzuki YJ, Mizuno M, Tritschler HJ, Packer L. Redox regulation of NF-kappa B DNA binding activity by dihydrolipoate. Biochem Mol Biol Int 1995; 36: 241-46.
35. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15: 2423-32.
36. He C. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter. Cancer Lett 1996; 106 185-91.
37. Voraberger G, Schafer R, Stratowa C. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region. Induction by cytokines and phorbol ester. J Immunol 1991; 147: 2777-86.
38. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997; 48: 1557-65.
39. Bilinska M, Frydecka I, Podemski R. Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients. Neurol Neurochir Pol 2001; 35: 47-56.
40. Giorelli M, De Blasi A, Defazio G, Avolio C, Iacovelli L, Livrea P et al. Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. Cell Commun Adhes 2002; 9: 259-72.
41. Lyons PD, Benveniste EN. Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 1998; 22: 103-12.
42. Hermann R, Niebch G, Borbe HO, Fieger-Buschges H, Russ P, Nowak H et al. Enantioselective pharmacokinetics and bioavailability of different racemic alpha lipoic acid formulations in healthy volunteers. Eur J Pharm Sci 1996; 4: 167-74.
43. Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 1998; 36: 625-28.
44. Gleiter CH, Schug BS, Hermann R, Elze M, Blume HH, Gundert-Remy U. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol 1996; 50: 513-14.
45. Ziegler D, Hanefeld M, Ruhnau K, Meissner HP, Lobisch M, Schutte K et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.
46. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402-408.
47. Kilinc M, Saatci-Cekirge I, Karabudak R. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment. J Interferon Cytokine Res 2003; 23: 127-33.